Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
Valgimigli M, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo DJ, Sabatè M, Ferrari F, Furgieri A, Tumscitz C, Repetto A, Colangelo S, Meliga E, Kubbajeh M, Parrinello G, Percoco G, Ferrari R. Valgimigli M, et al. Among authors: campo g. Cardiovasc Drugs Ther. 2008 Aug;22(4):313-20. doi: 10.1007/s10557-008-6121-z. Epub 2008 Jun 17. Cardiovasc Drugs Ther. 2008. PMID: 18561010 Clinical Trial.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Among authors: campo g. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.
Abciximab: a reappraisal of its use in coronary care.
Valgimigli M, Campo G, Tebaldi M, Carletti R, Arcozzi C, Ferrari R, Percoco G. Valgimigli M, et al. Among authors: campo g. Biologics. 2008 Mar;2(1):29-39. doi: 10.2147/btt.s1374. Biologics. 2008. PMID: 19707425 Free PMC article.
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.
Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Valgimigli M, et al. Among authors: campo g. Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. Eur Heart J. 2010. PMID: 19755402 Review.
The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction.
Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M; STRATEGY Investigators. Tebaldi M, et al. Among authors: campo g. J Am Coll Cardiol. 2009 Nov 10;54(20):1900-1. doi: 10.1016/j.jacc.2009.08.009. J Am Coll Cardiol. 2009. PMID: 19892243 Free article. No abstract available.
758 results